Drug · DIN 02312557
BOOSTRIX-POLIO
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 22, 2010; first marketed October 22, 2010.
- Drug Identification Number (DIN)
- 02312557
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Schedule D
- Dosage form
- Suspension
- Route
- Intramuscular
- Therapeutic class (ATC)
- Diphtheria-pertussis-poliomyelitis-tetanus J07CA02
- Class
- Human
- Record last updated
- June 16, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DIPHTHERIA TOXOID ADSORBED | 2.5 LF | 0.5 ML |
| TETANUS TOXOID ADSORBED | 5.0 LF | 0.5 ML |
| PERTUSSIS TOXOID ADSORBED | 8 MCG | 0.5 ML |
| FILAMENTOUS HAEMAGGLUTININ ADSORBED | 8 MCG | 0.5 ML |
| PERTACTIN ADSORBED | 2.5 MCG | 0.5 ML |
| INACTIVATED POLIOVIRUS TYPE I | 40 D | 0.5 ML |
| INACTIVATED POLIOVIRUS TYPE II | 8 D | 0.5 ML |
| INACTIVATED POLIOVIRUS TYPE III | 32 D | 0.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- June 12, 2008: NOC 9612New Drug Submission (NDS)